ALPHAMAB-B(09966),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

09966 ALPHAMAB-B

Trading 09-03 14:21:48

8.750

+0.180

+2.10%

High8.785	Low8.515	Vol422.00K
Open8.615	D1 Closing8.570	Amplitude3.15%
Mkt Cap8.47B	Tradable Cap8.47B	Total Shares968.00M
T/O3.64M	T/O Rate0.04%	Tradable Shares968.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"09966","market":"HK","secType":"STK","nameCN":"ALPHAMAB-B","latestPrice":8.75,"timestamp":1788416458820,"preClose":8.57,"halted":0,"volume":422000,"delay":0,"changeRate":0.021003500583430538,"floatShares":968000000,"shares":968000000,"eps":-0.14008359538578566,"marketStatus":"Trading","change":0.18,"latestTime":"09-03 14:21:48","open":8.615,"high":8.785,"low":8.515,"amount":3636543,"amplitude":0.031505,"askPrice":8.75,"askSize":4000,"bidPrice":8.715,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":-0.21294691016240716,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788423000000},"marketStatusCode":2,"adr":0,"listingDate":1576080000000,"exchange":"SEHK","adjPreClose":8.57,"openAndCloseTimeList":[[1788399000000,1788408000000],[1788411600000,1788422400000]],"volumeRatio":0.286588,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09966","defaultTab":"news","newsList":[{"id":"1130240076","title":"Alphamab Oncology Buys Back 115,000 Shares, Lifting Treasury Stock to 6.22 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1130240076","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130240076?lang=en_us&edition=fundamental","pubTime":"2026-09-02 23:22","pubTimestamp":1788362554,"startTime":"0","endTime":"0","summary":"Alphamab Oncology (Alphamab) disclosed that it repurchased 115,000 ordinary shares on 2 September 2026 through on-market transactions on the Hong Kong Stock Exchange. The shares were acquired at...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664817416","title":"Alphamab Oncology Files HKEX Next-Day Disclosure Return for Share Buyback at HKD 8.57","url":"https://stock-news.laohu8.com/highlight/detail?id=2664817416","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664817416?lang=en_us&edition=fundamental","pubTime":"2026-09-02 22:27","pubTimestamp":1788359260,"startTime":"0","endTime":"0","summary":"Alphamab Oncology files HKEX next-day disclosure return for share buyback at HKD 8.57Alphamab Oncology repurchased 115,000 shares on Sept. 2, holding them as treasury shares; no shares were cancelled.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL3rSzX6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09966","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193934476","title":"Alphamab Oncology Buys Back 115,000 Shares for HKD 0.98 Million, Lifts Treasury Stock to 6.10 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1193934476","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193934476?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:02","pubTimestamp":1788264137,"startTime":"0","endTime":"0","summary":"Alphamab Oncology disclosed a share repurchase on 1 September 2026, buying back 115,000 ordinary shares on the Hong Kong Stock Exchange at prices ranging between HKD 8.48 and HKD 8.54. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663003766","title":"Alphamab Oncology Files HKEX Next-Day Disclosure Return Reporting Share Repurchase at HKD 8.9 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2663003766","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663003766?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:46","pubTimestamp":1788180401,"startTime":"0","endTime":"0","summary":"Alphamab Oncology files HKEX next-day disclosure return reporting share repurchase at HKD 8.9 eachAlphamab Oncology repurchased 110,000 ordinary shares on HKEX on Aug. 31, 2026 for treasury.Buyback pr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL3kwvC4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122962978","title":"Alphamab Oncology Launches HK$80.00 Million On-Market Share Repurchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1122962978","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122962978?lang=en_us&edition=fundamental","pubTime":"2026-08-28 22:01","pubTimestamp":1787925708,"startTime":"0","endTime":"0","summary":"Alphamab Oncology has approved an on-market share repurchase program of up to HK$80.00 million, aiming to buy back ordinary shares on the Hong Kong Stock Exchange. The decision, resolved by the Board...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662096191","title":"Alphamab Oncology - Board Resolves to Repurchase Shares up to HK$80 Mln in Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2662096191","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662096191?lang=en_us&edition=fundamental","pubTime":"2026-08-28 21:56","pubTimestamp":1787925376,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44P1XZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","09966","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662509616","title":"Alphamab Oncology Launches On-Market Share Buyback of up to HK$ 80 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662509616","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662509616?lang=en_us&edition=fundamental","pubTime":"2026-08-28 21:55","pubTimestamp":1787925346,"startTime":"0","endTime":"0","summary":"Alphamab Oncology launches on-market share buyback of up to HK$ 80 millionAlphamab Oncology authorized an on-market share buyback of up to HK$80 million, starting Aug. 28, 2026.Repurchases will be fun","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL21zqMG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09966","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662935380","title":"Alphamab Oncology (SEHK:9966) Stock Rally Meets Revenue Dip And Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2662935380","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662935380?lang=en_us&edition=fundamental","pubTime":"2026-08-28 19:32","pubTimestamp":1787916728,"startTime":"0","endTime":"0","summary":"Alphamab Oncology stock has been on a short run higher, with the shares up about 15% over the past month. However, today’s earnings send a very different message. The headline is simple: revenue for the first half of 2026 came in at ¥271.2m, while the company reported a net loss of ¥40.5m and a basic loss per share of ¥0.04.\nFor a biotech that still trades on revenue potential more than profit, this contrast between top line and continuing losses is what the market is really reacting to. The...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/alphamab-oncology-sehk9966-stock-rally-meets-revenue-dip-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/alphamab-oncology-sehk9966-stock-rally-meets-revenue-dip-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PMDE","JOYT","FEBU","RGLO","GXDW","BK1161","BK1574","DECU","VGFPF","VOTE","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662033496","title":"Why Alphamab Oncology (SEHK:9966) Is Up 9.2% After Priority Review For Anbenitamab In HER2 Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662033496","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662033496?lang=en_us&edition=fundamental","pubTime":"2026-08-28 03:29","pubTimestamp":1787858983,"startTime":"0","endTime":"0","summary":"Alphamab Oncology recently reported half-year 2026 results showing CNY 271.24 million in sales and a net loss of CNY 40.46 million, while also securing Chinese priority review for multiple Anbenitamab new drug applications in HER2-positive breast cancer.\nThe acceptance of these Anbenitamab applications, backed by a head-to-head phase III trial in advanced HER2-positive breast cancer, marks a rare case where a bispecific antibody combination outperformed the long-standing THP standard regimen...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/why-alphamab-oncology-sehk9966-is-up-92-after-priority-revie","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/why-alphamab-oncology-sehk9966-is-up-92-after-priority-revie","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","BK1161","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169611235","title":"Alphamab Oncology Reports RMB40.46 Million 1H26 Loss Amid 15% Revenue Drop; Cash at RMB1.43 Billion Supports Expanding Oncology Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=1169611235","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169611235?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:21","pubTimestamp":1787840514,"startTime":"0","endTime":"0","summary":"Alphamab Oncology released unaudited results for the six months ended 30 June 2026, showing a return to red ink as revenue contracted and royalty income softened, while research and development (R&D)...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alphamab Oncology Reports RMB40.46 Million 1H26 Loss Amid 15% Revenue Drop; Cash at RMB1.43 Billion Supports Expanding Oncology Pipeline","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662608309","title":"Alphamab Oncology Swings to FY26 H1 Loss of RMB 40.46 Million; Revenue Falls 15.09% to RMB 271.24 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662608309","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662608309?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:03","pubTimestamp":1787839411,"startTime":"0","endTime":"0","summary":"Alphamab Oncology swings to FY26 H1 loss of RMB 40.46 million; revenue falls 15.09% to RMB 271.24 millionAlphamab Oncology posted a loss of RMB 40.46 million, swinging from a profit of RMB 21.58 milli","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL6fG19l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09966","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136334991","title":"HK Movers | Biotech Stocks Jump. CANSINOBIO Surges 17%; Innovent Bio up 11%; Akeso up over 8%; Everest Med up 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1136334991","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136334991?lang=en_us&edition=fundamental","pubTime":"2026-08-26 09:47","pubTimestamp":1787708820,"startTime":"0","endTime":"0","summary":"Biotech stocks jumped in Hong Kong market. CANSINOBIO surged 17%; Innovent Bio up 11%; Akeso up over 8%; Everest Med up 7%.On the news front, $CANSINOBIO(06185)$ announced on August 25 that its...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"330240692f324d079ccf839d9e4180bf","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268","02137","09606","06606","09966","02359","03347","09995","02269","01672","09688","06978","03759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175281752","title":"Alphamab's KN026 Combination Therapy for First-Line HER2-Positive Advanced Breast Cancer Receives NMPA Filing Acceptance","url":"https://stock-news.laohu8.com/highlight/detail?id=1175281752","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175281752?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:06","pubTimestamp":1787047597,"startTime":"0","endTime":"0","summary":"ALPHAMAB-B (09966) has announced that the New Drug Application (NDA) for anitumomab (trade name: Enituo, development code: KN026) in combination with docetaxel injection (albumin-bound) (HB1801) for...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","IPOS","BK1161","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660146646","title":"Alphamab Oncology Says China NMPA Accepts Anbenitamab NDA for First-Line HER2+ Advanced Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2660146646","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660146646?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:01","pubTimestamp":1787047294,"startTime":"0","endTime":"0","summary":"Alphamab Oncology says China NMPA accepts Anbenitamab NDA for first-line HER2+ advanced breast cancerChina’s NMPA accepted an NDA for anbenitamab (KN026) plus albumin-bound docetaxel HB1801 in first-l","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDL8jzLgj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0008368742.USD","LU1226287792.SGD","LU1226288170.HKD","LU1152091168.USD","01093","LU0880133367.SGD","LU1951186391.HKD","BK1574","LU2039709279.SGD","BK1191","LU0140636845.USD","LU0326950275.SGD","LU1807302812.USD","LU1226288253.USD","IE0008369823.USD","IE00BZ08YR35.GBP","LU1813983027.USD","BK1161","LU0315179316.USD","09966","IE00B543WZ88.USD","IE00BZ08YS42.EUR","LU1328277881.USD","LU1226287529.USD","LU1993786604.SGD","LU0501845795.SGD","KURE","BK1521","LU1008478684.HKD","LU0314109678.HKD","HK0000165453.HKD","LU1226287875.USD","LU0072913022.USD","IE00B5MMRT66.SGD","LU0067412154.USD","BK1515","IE00BZ08YT58.USD","IE00B031HY20.USD","LU1960683339.HKD","LU1152091754.HKD","SG9999004220.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660466130","title":"Alphamab Oncology - Nmpa Accepts Nda for Anbenitamab (Kn026) with Hb1801 for Her2+ Advanced Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2660466130","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660466130?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:00","pubTimestamp":1787047230,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nFWN44F0FD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09966","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658920308","title":"Alphamab Oncology Schedules Board Meeting to Review Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658920308","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658920308?lang=en_us&edition=fundamental","pubTime":"2026-08-12 16:36","pubTimestamp":1786523777,"startTime":"0","endTime":"0","summary":"Alphamab Oncology schedules board meeting to review interim resultsAlphamab Oncology scheduled a board meeting for Aug. 27, 2026 to review interim results for the six months ended June 30, 2026.Discla","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL4YBHQZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657084510","title":"Alphamab Oncology Licenses Cancer Drug Candidate to Pathos AI for Up to $2.09 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2657084510","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657084510?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:04","pubTimestamp":1785924260,"startTime":"0","endTime":"0","summary":"Alphamab Oncology's  wholly owned subsidiary, Jiangsu Alphamab Biopharmaceuticals, has granted Pathos AI an exclusive license to develop and commercialize cancer drug JSKN016 outside mainland China, Hong Kong, Macau and Taiwan, in a deal worth up to $2.09 billion.Under the agreement, Alphamab will receive a $125 million upfront payment and is eligible for additional milestone payments and tiered royalties based on sales in the licensed markets, according to a Hong Kong bourse filing.As part of the deal, Pathos AI granted Alphamab an option to invest up to $62.5 million in its preferred shares.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AGIX","09966","BK1574","ARTY","AIPO","CHAT","VTHR","BK1161","QTOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135953507","title":"Alphamab Oncology (ALPHAMAB-B) Reports Stable Share Capital and Option Movements for July 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1135953507","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135953507?lang=en_us&edition=fundamental","pubTime":"2026-08-05 17:29","pubTimestamp":1785922177,"startTime":"0","endTime":"0","summary":"Alphamab Oncology filed its monthly return to Hong Kong Exchanges and Clearing Limited for the period ended 31 July 2026. The filing shows no changes in either authorised or issued share capital...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656558078","title":"CSPC Pharma Unit, Alphamab Oncology's Breast Cancer Drug Application Granted Priority Review in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2656558078","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656558078?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:34","pubTimestamp":1785843297,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical  said a new drug application for Anbenitamab was accepted by China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The application for Anbenitamab, co-developed by Shanghai JMT-Bio Technology, a unit of the company, and Alphamab Oncology , has also been included in the priority review and approval procedures.The indication for the application is Anbenitamab in combination with docetaxel  ± carboplatin as neoadjuvant therapy to treat breast cancer in adults.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1226287875.USD","LU0501845795.SGD","LU1960683339.HKD","LU0314109678.HKD","LU1226288253.USD","LU0140636845.USD","BK1521","LU1951186391.HKD","01093","LU1813983027.USD","IE00B5MMRT66.SGD","LU1226287792.SGD","HK0000165453.HKD","LU1226287529.USD","IE0008369823.USD","LU1226288170.HKD","BK1574","IE00B031HY20.USD","BK1191","LU0326950275.SGD","LU1328277881.USD","LU1152091754.HKD","IE00BZ08YR35.GBP","LU1008478684.HKD","IE00B543WZ88.USD","LU1152091168.USD","BK1515","LU0067412154.USD","SG9999004220.SGD","LU0315179316.USD","LU2039709279.SGD","LU1807302812.USD","KURE","LU1993786604.SGD","LU0072913022.USD","09966","BK1161","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","IE0008368742.USD","LU0880133367.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116442889","title":"ALPHAMAB-B's Novel Drug Application for Anniutuo (KN026) in HER2-Positive Breast Cancer Neoadjuvant Therapy Accepted by Chinese Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=1116442889","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116442889?lang=en_us&edition=fundamental","pubTime":"2026-08-04 18:11","pubTimestamp":1785838261,"startTime":"0","endTime":"0","summary":"ALPHAMAB-B (09966.HK) announced that the New Drug Application (NDA) for Anniutuo (brand name: Ennituo®, development code: KN026), developed in collaboration with CSPC Pharmaceutical Group (01093.HK)...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1161","BK1574","IPOS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alphamab.com","stockEarnings":[{"period":"1week","weight":0.0136},{"period":"1month","weight":0.1581},{"period":"3month","weight":0.1986},{"period":"6month","weight":0.0917},{"period":"1year","weight":-0.0715},{"period":"ytd","weight":-0.1255}],"compareEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0268},{"period":"3month","weight":0.0023},{"period":"6month","weight":-0.0173},{"period":"1year","weight":-0.0073},{"period":"ytd","weight":-0.0125}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Alphamab Oncology is an investment holding company principally engaged in research and development, manufacturing and commercialisation of biologics of oncology. The Company’s in-house pipeline consists of antibody-drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies in staggered development status in oncology. The Company’s product pipeline includes KN046 (PD-L1/CTLA-4 bispecific antibody), KN026 (HER2/HER2 bispecific antibody), KN035 (SubQ PD-L1), JSKN003 (HER2 biparatopic ADC), JSKN016(HER3/TROP2 bispecific antibody ADC), JSKN033(subcutaneous co-formulation of JSKN003 and KN035), used for indications such as 1L sq NSCLC, 1L HER2+ BC, 1L biliary track cancer, advanced solid tumors, HER2-expressing solid tumors and others.","yearOnYearQuotes":[{"month":1,"riseRate":0.142857,"avgChangeRate":-0.117313},{"month":2,"riseRate":0.571429,"avgChangeRate":0.192959},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.039472},{"month":4,"riseRate":0.857143,"avgChangeRate":0.098183},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.031094},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.059361},{"month":7,"riseRate":0.428571,"avgChangeRate":0.061567},{"month":8,"riseRate":0.428571,"avgChangeRate":0.047929},{"month":9,"riseRate":0.285714,"avgChangeRate":0.129408},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.030396},{"month":11,"riseRate":0.5,"avgChangeRate":0.042537},{"month":12,"riseRate":0.5,"avgChangeRate":-0.017716}],"exchange":"SEHK","name":"ALPHAMAB-B","nameEN":"ALPHAMAB-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ALPHAMAB-B(09966),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ALPHAMAB-B(09966) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ALPHAMAB-B,09966,ALPHAMAB-B股票,ALPHAMAB-B股票老虎,ALPHAMAB-B股票老虎国际,ALPHAMAB-B行情,ALPHAMAB-B股票行情,ALPHAMAB-B股价,ALPHAMAB-B股市,ALPHAMAB-B股票价格,ALPHAMAB-B股票交易,ALPHAMAB-B股票购买,ALPHAMAB-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ALPHAMAB-B(09966),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ALPHAMAB-B(09966) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}